On behalf of BTG International Inc., I respectfully request the NCCN Panel on Non-Hodgkin Lymphoma (NHL) to review the enclosed data for inclusion of VORAXAZE® (glucarpidase) for the treatment of toxic plasma methotrexate (MTX) concentrations in NHL patients receiving high-dose methotrexate therapy and who have delayed methotrexate clearance due to impaired renal function. Of the 243 patients in whom glucarpidase was administered under the Vora™ US Open-Label Treatment Protocol IND (as of Oct. 2010), 23% had received high dose methotrexate for treatment for non-Hodgkin lymphoma, predominantly Burkitt’s, mantle cell and diffuse large B-cell lymphomas.

Specific Changes: Recommend the use of glucarpidase in patients who have received high-dose methotrexate and are experiencing delayed elimination of methotrexate (concentration >1 micromole per liter) due to impaired renal function.

FDA Clearance Status: Glucarpidase was approved on January 17, 2012 for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function and is commercially available in the United States as of April 30, 2012.

Rationale: Methotrexate-associated renal impairment is an oncologic emergency that continues to occur despite the best medical management. Frequencies of Common Terminology Criteria for Adverse Events Grade ≥2 nephrotoxicity depend on tumor type and patient age, and range from 1.8% in pediatric patients being treated for osteosarcoma (Widemann 2004, 2010) to 24% in elderly patients being treated for primary central nervous system lymphoma (Schwartz 2007). These data include patients treated after 1980, when management began to routinely include IV hydration, urinary alkalinization and leucovorin rescue.

Glucarpidase hydrolyzes the terminal glutamate residue from naturally-occurring folates and folate analogs such as MTX. The hydrolysis of MTX and its active metabolite, 7-hydroxymethotrexate (7-OH MTX), by glucarpidase forms inactive metabolites, including glutamate, 2,4-diamino-N10-methylpterolic acid (DAMPA), and 7-hydroxy DAMPA (7-OH DAMPA).
DAMPA), which are eliminated from the body through non-renal mechanisms; therefore, in patients with impaired renal function who are unable to clear MTX efficiently, treatment with glucarpidase therefore provides an alternate route of MTX clearance (Christensen, 2012). In data published by the National Cancer Institute on 100 patients, plasma MTX concentrations decreased within 15 minutes of glucarpidase administration by 98.7% (Widemann, 2010). BTG International’s Biologics Licensing Application (approved in 2012) presented an efficacy analysis of 156 patients where, at the first measurement (median 15 minutes post-glucarpidase), plasma MTX was reduced by a median of 99% relative to their pre-glucarpidase baseline. At the last measurement (median 40 hours post-glucarpidase) median plasma MTX reduction remained at 99% compared with baseline measurement. The BLA data are embargoed in anticipation of being presented at the American Society for Clinical Oncology (ASCO) 2012 Annual Congress in June, but will be provided to the NCCN Panel after the presentation at ASCO and prior to the Panel’s meeting.

The following citations are submitted in support of this proposed change.


Glucarpidase has been available in the clinic in the US since 1993 via compassionate use protocols. We would like to acknowledge the NCCN panel members who, by requesting or prescribing glucarpidase to their patients through our compassionate use program, directly contributed to the development of glucarpidase: Nancy Bartlett MD, Jon Glockerman MD, Pierluigi Porcu MD, and Lubomir Sokol MD PhD.

Sincerely,

Emmanuel M. Mahlis MD
VP Medical Affairs
BTG International Inc